Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Short Interest Update

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) was the recipient of a large decline in short interest in December. As of December 15th, there was short interest totalling 493,500 shares, a decline of 6.0% from the November 30th total of 525,000 shares. Based on an average trading volume of 65,000 shares, the days-to-cover ratio is currently 7.6 days. Approximately 3.2% of the company’s stock are short sold.

Insider Buying and Selling

In related news, Director John Patience purchased 200,000 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were acquired at an average price of $1.57 per share, for a total transaction of $314,000.00. Following the purchase, the director now owns 653,224 shares of the company’s stock, valued at $1,025,561.68. This trade represents a 44.13 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 43.60% of the stock is currently owned by company insiders.

Institutional Trading of Accelerate Diagnostics

An institutional investor recently bought a new position in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd acquired a new position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned 0.08% of Accelerate Diagnostics at the end of the most recent reporting period. 17.14% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

AXDX has been the topic of a number of recent analyst reports. StockNews.com initiated coverage on shares of Accelerate Diagnostics in a research note on Friday, December 27th. They set a “hold” rating on the stock. BTIG Research upgraded shares of Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th.

Accelerate Diagnostics Price Performance

NASDAQ:AXDX opened at $1.20 on Thursday. The firm has a market capitalization of $30.05 million, a P/E ratio of -0.42 and a beta of 0.56. Accelerate Diagnostics has a 1-year low of $0.73 and a 1-year high of $4.24. The company’s fifty day moving average price is $1.58 and its 200-day moving average price is $1.54.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.